- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
NCI to review screening guidelines
The National Cancer Institute this month plans to revisit itscontroversial decision not to recommend mammography screeningfor women aged 40 to 49. The NCI is scheduled to hold a consensusdevelopment conference on the topic Jan. 21-23 in Bethesda, MD.The
The National Cancer Institute this month plans to revisit itscontroversial decision not to recommend mammography screeningfor women aged 40 to 49. The NCI is scheduled to hold a consensusdevelopment conference on the topic Jan. 21-23 in Bethesda, MD.
The NCI in 1993 withdrew its recommendation that women aged 40to 49 receive screening mammograms every one to two years (SCAN12/15/93). The move conflicted with screening guidelines fromgroups such as the American College of Radiology and AmericanCancer Society, and drew heavy criticism.
Several studies have been published since then suggesting thatmammography screening of younger women could reduce the deathrate from breast cancer. This month's conference will review thosedata, and will examine whether or not the NCI's guidelines shouldbe changed accordingly, an NCI spokesperson said.
The conference will take place at the Natcher Conference Centerat the National Institutes of Health, Building 45, 9000 RockvillePike, Bethesda. For registration information contact Hope LevyKott at Technical Resources International, 301/468-2245.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
